Literature DB >> 23575768

Guillain-barré syndrome.

Mazen M Dimachkie1, Richard J Barohn.   

Abstract

OPINION STATEMENT: Acute Inflammatory polyneuropathies are an important group of neuromuscular disorders and are referred to collectively as Guillain-Barré syndrome (GBS). Our knowledge regarding pathogenesis, diagnosis and management continues to expand, resulting in improved opportunities for identification and treatment. These autoimmune processes cause neuropathy by affecting various structures (myelin or axons), at different locations (nerve root, nerve cell bodies or peripheral nerve) with a variety of patterns. Most clinical neurologists will be involved in the management of patients with these disorders, and there are now a variety of reasonable therapies available for acquired demyelinating neuropathies. In this report, we review the distinctive clinical, laboratory and electro-diagnostic features that aid in their diagnosis, with emphasis on clinical characteristics that are of paramount importance in diagnosing specific conditions and determining the most appropriate therapies, and helpful in determining long-term prognosis.

Entities:  

Year:  2013        PMID: 23575768     DOI: 10.1007/s11940-013-0231-z

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  65 in total

1.  Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation.

Authors:  J Pritchard; R Mukherjee; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-09       Impact factor: 10.154

2.  Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands.

Authors:  R Van Koningsveld; P A Van Doorn; P I Schmitz; C W Ang; F G Van der Meché
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

3.  Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP.

Authors:  Eleni E Magira; Miltiadis Papaioakim; Irving Nachamkin; Arthur K Asbury; Chun Y Li; Tony W Ho; John W Griffin; Guy M McKhann; Dimitri S Monos
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

4.  Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.

Authors:  L Ruts; J Drenthen; B C Jacobs; P A van Doorn
Journal:  Neurology       Date:  2010-04-28       Impact factor: 9.910

5.  Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group.

Authors:  L H Visser; P I Schmitz; J Meulstee; P A van Doorn; F G van der Meché
Journal:  Neurology       Date:  1999-08-11       Impact factor: 9.910

6.  Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  R A C Hughes; E F M Wijdicks; R Barohn; E Benson; D R Cornblath; A F Hahn; J M Meythaler; R G Miller; J T Sladky; J C Stevens
Journal:  Neurology       Date:  2003-09-23       Impact factor: 9.910

7.  Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside.

Authors:  H J Willison; J Veitch; G Paterson; P G Kennedy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-02       Impact factor: 10.154

8.  Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

Authors:  R D Hadden; D R Cornblath; R A Hughes; J Zielasek; H P Hartung; K V Toyka; A V Swan
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422

9.  Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977.

Authors:  L B Schonberger; D J Bregman; J Z Sullivan-Bolyai; R A Keenlyside; D W Ziegler; H F Retailliau; D L Eddins; J A Bryan
Journal:  Am J Epidemiol       Date:  1979-08       Impact factor: 4.897

10.  Unusual clinical variants and signs in Guillain-Barré syndrome.

Authors:  A H Ropper
Journal:  Arch Neurol       Date:  1986-11
View more
  3 in total

Review 1.  Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention.

Authors:  Eroboghene E Ubogu
Journal:  Acta Neuropathol       Date:  2015-08-12       Impact factor: 17.088

2.  A new animal model of spontaneous autoimmune peripheral polyneuropathy: implications for Guillain-Barré syndrome.

Authors:  Mu Yang; Anthony Rainone; Xiang Qun Shi; Sylvie Fournier; Ji Zhang
Journal:  Acta Neuropathol Commun       Date:  2014-01-08       Impact factor: 7.801

3.  Long-term outcomes of Guillain-Barré syndrome possibly associated with Zika virus infection.

Authors:  Diana M Walteros; Jesus Soares; Ashley R Styczynski; Joseph Y Abrams; Jose I Galindo-Buitrago; Jorge Acosta-Reyes; Elsa Bravo-Ribero; Zuleima E Arteta; Alma Solano-Sanchez; Franklyn E Prieto; Maritza Gonzalez-Duarte; Edgar Navarro-Lechuga; Jorge L Salinas; Ermias D Belay; Lawrence B Schonberger; Inger K Damon; Martha L Ospina; James J Sejvar
Journal:  PLoS One       Date:  2019-08-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.